#United States #Miami #Pacira BioSciences #DOMA Perpetual #shareholder activism

DOMA Perpetual Calls for Change in Pacira BioSciences Board Leadership

DOMA Perpetual Capital Management, an investment firm focused on value creation, is expressing grave concerns regarding the Board of Directors at Pacira BioSciences, Inc. This comes in light of a decade characterized by significant declines in shareholder value and questionable management decisions. DOMA, which holds approximately 7.5% of Pacira’s outstanding shares, is urging fellow shareholders to consider the implications of voting to retain a Board that has overseen considerable financial deterioration.

Financial Decline and Mismanagement

Recent financial trends indicate a troubling decline in Pacira's stock price across various time frames. For instance, the stock reported a staggering -65% return over the past five years and a concerning -46% over the past decade. These figures starkly contrast with the ongoing compensation increases received by the Board and management, raising questions about their effectiveness and accountability in driving value for shareholders.

DOMA highlights that despite Pacira's assertions about the strength of its patent portfolio, market reactions suggest that investors remain unconvinced. This disconnect is alarming, particularly when considering the significant implications of a recent patent loss for the company. As Pacira prepares for ongoing litigation and potential setbacks in its patent disputes, the risks facing its business are becoming increasingly evident.

Concerns Over Management Transparency

In their communications, DOMA alleges that the current management misled shareholders regarding the competitive threats presented by generics. Notably, the settlement with Fresenius Kabi, which was portrayed as a positive development, has left stakeholders questioning the depth of management's understanding of the market's dynamics. Critics argue that the company is inadequately addressing the potential ramifications of further legal defeats, particularly concerning EXPAREL, a drug that contributes significantly to Pacira's revenue.

The firm raised concerns that management’s lack of a coherent risk management strategy might endanger the business’s future. If a more dominant competitor dominates the market, Pacira’s financial standing may deteriorate further, jeopardizing its operational viability.

Call for Strategic Alternatives

DOMA is advocating for a more proactive approach to governance, suggesting that exploring strategic alternatives, including a potential sale, could help safeguard stakeholder interests and restore shareholder value. It asserts that the Board's resistance to considering a sale appears driven by the desire to maintain positions of power rather than prioritize shareholder returns.

The investment firm emphasizes the need for new leadership at Pacira to reinvigorate discussions about its strategic direction and to genuinely evaluate all potential paths to maximize shareholder value. They are urging all shareholders to vote in favor of new nominees proposed by DOMA, which they believe will bring fresh perspectives and a renewed commitment to transparency and accountability.

In conclusion, DOMA Perpetual Capital Management is making a strong case for shareholders to reconsider their support of current Board leadership at Pacira BioSciences. As the annual meeting approaches, the stakes for shareholders couldn’t be higher, underscoring the importance of informed voting to ensure that their interests are adequately protected.